Analysts Issue Forecasts for Fractyl Health Q3 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Investment analysts at HC Wainwright issued their Q3 2025 earnings estimates for Fractyl Health in a report released on Monday, September 15th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.35) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($1.32) EPS, FY2028 earnings at ($1.28) EPS and FY2029 earnings at ($1.36) EPS.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Fractyl Health had a negative return on equity of 584.35% and a negative net margin of 73,864.52%.

GUTS has been the subject of several other reports. LADENBURG THALM/SH SH assumed coverage on shares of Fractyl Health in a report on Thursday, August 28th. They issued a “buy” rating and a $3.60 target price for the company. Canaccord Genuity Group decreased their target price on shares of Fractyl Health from $12.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fractyl Health has a consensus rating of “Buy” and a consensus target price of $7.15.

Fractyl Health Stock Performance

Shares of GUTS opened at $0.97 on Wednesday. Fractyl Health has a one year low of $0.83 and a one year high of $3.48. The company has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.45. The stock has a market cap of $48.90 million, a price-to-earnings ratio of -0.47 and a beta of 1.55. The company has a debt-to-equity ratio of 4.61, a current ratio of 1.22 and a quick ratio of 1.22.

Hedge Funds Weigh In On Fractyl Health

Institutional investors have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd bought a new position in shares of Fractyl Health in the second quarter valued at approximately $26,000. Jane Street Group LLC bought a new position in shares of Fractyl Health in the second quarter valued at approximately $31,000. Chicago Partners Investment Group LLC bought a new position in shares of Fractyl Health in the first quarter valued at approximately $37,000. HighTower Advisors LLC raised its position in shares of Fractyl Health by 57.9% in the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company’s stock valued at $49,000 after purchasing an additional 15,000 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Fractyl Health by 54.5% in the first quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company’s stock valued at $76,000 after purchasing an additional 22,572 shares during the period.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.